StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report report published on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Marinus Pharmaceuticals Stock Down 0.2 %
MRNS opened at $0.55 on Thursday. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $8.45. The business has a fifty day simple moving average of $0.55 and a 200-day simple moving average of $0.68. The firm has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.
Institutional Trading of Marinus Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Woodline Partners LP grew its holdings in shares of Marinus Pharmaceuticals by 84.7% in the fourth quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock valued at $1,250,000 after purchasing an additional 1,071,410 shares in the last quarter. Beryl Capital Management LLC purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth $2,262,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at $54,000. XTX Topco Ltd boosted its holdings in Marinus Pharmaceuticals by 1,564.7% in the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 206,614 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Marinus Pharmaceuticals by 266.1% during the 4th quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 354,393 shares during the period. 98.80% of the stock is currently owned by hedge funds and other institutional investors.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Further Reading
- Five stocks we like better than Marinus Pharmaceuticals
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Investing In Preferred Stock vs. Common Stock
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- 3 Tickers Leading a Meme Stock Revival
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
